Bicycle Therapeutics plc
BCYC
$4.10
$0.092.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 63.50M | 72.59M | 28.34M | 19.28M | 25.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.50M | 72.59M | 28.34M | 19.28M | 25.72M |
| Cost of Revenue | 220.51M | 230.83M | 232.88M | 221.92M | 190.95M |
| Gross Profit | -157.02M | -158.24M | -204.54M | -202.63M | -165.22M |
| SG&A Expenses | 81.13M | 84.62M | 84.38M | 84.58M | 82.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 301.64M | 315.45M | 317.26M | 306.50M | 272.98M |
| Operating Income | -238.14M | -242.87M | -288.92M | -287.22M | -247.26M |
| Income Before Tax | -217.62M | -218.81M | -252.86M | -248.21M | -208.72M |
| Income Tax Expenses | 1.41M | 152.00K | -2.20M | -5.85M | -5.50M |
| Earnings from Continuing Operations | -219.03 | -218.96 | -250.66 | -242.36 | -203.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.03M | -218.96M | -250.66M | -242.36M | -203.22M |
| EBIT | -238.14M | -242.87M | -288.92M | -287.22M | -247.26M |
| EBITDA | -232.23M | -236.44M | -282.13M | -280.01M | -240.11M |
| EPS Basic | -3.16 | -3.16 | -3.62 | -3.51 | -3.13 |
| Normalized Basic EPS | -1.92 | -1.94 | -2.31 | -2.27 | -2.03 |
| EPS Diluted | -3.16 | -3.16 | -3.62 | -3.51 | -3.13 |
| Normalized Diluted EPS | -1.92 | -1.94 | -2.31 | -2.27 | -2.03 |
| Average Basic Shares Outstanding | 277.60M | 277.12M | 276.80M | 276.49M | 259.23M |
| Average Diluted Shares Outstanding | 277.60M | 277.12M | 276.80M | 276.49M | 259.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |